NRX Pharmaceuticals (NRXP) Income from Continuing Operations (2017 - 2026)
NRX Pharmaceuticals' (NRXP) quarterly Income from Continuing Operations came in at 4970000.0 in Q1 2026, down 29.33% year-on-year from 7032293.81 in Q1 2025, and down 7.58% on a QoQ basis from 4620000.0 in Q4 2025.
NRX Pharmaceuticals (NRXP) Income from Continuing Operations (2017 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has 10 years of Income from Continuing Operations data on file, last reported at 4970000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 29.33% year-over-year to 4970000.0 in Q1 2026; TTM through Mar 2026 was 17529000.0, a 7.32% decrease from a year earlier, with the FY2025 full-year figure at 67412000.0, up 1.04% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 4970000.0, down from 4620000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for NRXP reached as high as 2428000.0 in Q4 2024 and fell as low as 16711000.0 in Q1 2022.
- Historically, Income from Continuing Operations has averaged 6526882.35 across 5 years, with a median of 4970000.0 in 2026.
- Across the five-year window, Income from Continuing Operations slumped 8190.75% in 2022 and soared 76.26% in 2023, its largest moves.
- Year by year, Income from Continuing Operations stood at 12307000.0 in 2022, then jumped by 64.15% to 4412000.0 in 2023, then jumped by 44.97% to 2428000.0 in 2024, then sank by 90.28% to 4620000.0 in 2025, then fell by 7.58% to 4970000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 4970000.0 in Q1 2026, 4620000.0 in Q4 2025, and 4211000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | NRX Pharmaceuticals | 137.57 Mn | 130.87 Mn | 437,000.00 | -4.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.97 Mn |
| Dec 31, 2025 | -4.62 Mn |
| Sep 30, 2025 | -4.21 Mn |
| Jun 30, 2025 | -3.73 Mn |
| Mar 31, 2025 | -3.84 Mn |
| Dec 31, 2024 | -2.43 Mn |
| Sep 30, 2024 | -3.02 Mn |
| Jun 30, 2024 | -7.04 Mn |
| Mar 31, 2024 | -6.35 Mn |
| Dec 31, 2023 | -4.41 Mn |
| Sep 30, 2023 | -6.19 Mn |
| Jun 30, 2023 | -8.09 Mn |
| Mar 31, 2023 | -3.97 Mn |
| Dec 31, 2022 | -12.31 Mn |
| Sep 30, 2022 | -9.32 Mn |
| Jun 30, 2022 | -9.75 Mn |
| Mar 31, 2022 | -16.71 Mn |
| Dec 31, 2021 | -30.41 Mn |
| Sep 30, 2021 | -37.05 Mn |
| Jun 30, 2021 | -117,613.00 |